Pfizer (NYSE:PFE) Shares Up 2.6% – Still a Buy?

Pfizer Inc. (NYSE:PFE) shares shot up 2.6% on Friday . The company traded as high as $24.35 and last traded at $24.2750. Approximately 58,671,047 shares traded hands during trading, an increase of 38% from the average session volume of 42,401,559 shares. The stock had previously closed at $23.67.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Ibrance for frontline maintenance use in advanced breast cancer, giving Pfizer a modest commercial win and supporting revenue for an established oncology drug.
• Positive Sentiment: Pfizer declared its third-quarter 2026 dividend of $0.43 per share, reinforcing its appeal as a high-yield income stock and signaling confidence in cash flow.
• Positive Sentiment: Some recent analysis says a bullish case still makes sense despite the patent cliff, suggesting the stock may be attractive on valuation and dividend support.
• Neutral Sentiment: Pfizer has drawn increased trader attention, with Zacks noting that PFE is a trending stock as investors reassess its prospects.
• Neutral Sentiment: Pfizer Ventures helped lead a $62 million Series B for Oblenio Bio, a capital deployment that could create longer-term strategic optionality but is not likely to move the stock materially right away.
• Negative Sentiment: Pfizer halted a tafamidis bioequivalence study, which adds uncertainty around a potential formulation/clinical program and may be viewed as a setback for pipeline execution. Pfizer Halts Tafamidis Bioequivalence Study
• Negative Sentiment: Recent lung cancer trial disappointment in sigvotatug vedotin continues to weigh on sentiment, reinforcing fears that Pfizer may struggle to replace revenue lost to patent expirations.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. UBS Group reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. HSBC raised their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Guggenheim lifted their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Tuesday. Finally, Bank of America cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.82.

Pfizer Stock Performance

The firm’s fifty day simple moving average is $26.00 and its 200 day simple moving average is $26.30. The company has a market capitalization of $138.35 billion, a PE ratio of 18.53 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the business posted $0.92 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is currently 131.30%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently made changes to their positions in the company. Horizon Financial Services LLC grew its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer in the fourth quarter worth about $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer in the fourth quarter worth about $28,000. HFM Investment Advisors LLC boosted its stake in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. grew its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.